Technical Analysis for IPCI - Intellipharmaceutics International Inc.

Grade Last Price % Change Price Change
grade F 0.48 0.00% 0.00
IPCI closed unchanged on Friday, November 16, 2018, on 10 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Earnings due: Nov 20

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical IPCI trend table...

Date Alert Name Type % Chg
Nov 16 Hammer Candlestick Bullish 0.00%
Nov 16 Lizard Bullish Bullish Day Trade Setup 0.00%
Nov 16 Narrow Range Bar Range Contraction 0.00%
Nov 16 NR7 Range Contraction 0.00%
Nov 16 Doji - Bullish? Reversal 0.00%
Nov 16 Stochastic Reached Oversold Weakness 0.00%
Nov 16 Wide Bands Range Expansion 0.00%
Nov 16 Oversold Stochastic Weakness 0.00%
Nov 15 Narrow Range Bar Range Contraction 0.00%
Nov 15 Wide Bands Range Expansion 0.00%

Older signals for IPCI ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Intellipharmaceutics International Inc. engages in the research, development, and manufacture of novel and generic controlled and targeted release oral solid dosage drugs in Canada. It has a pipeline of products based on its patented Hypermatrix technology in various stages of development in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, and pain. The company's products under FDA review include Focalin XR, an extended release capsule for hyperactivity disorder; Effexor XR, an extended release capsule for depression; Protonix, a tablet for gastroesophageal reflux disease; Glucophage XR, a tablet for managing type 2 diabetes; Seroquel XR, a tablet for the treatment of schizophrenia, bipolar disorder, and depressive disorder; Lamictal XR, a tablet for anti-convulsant for epilepsy; and Keppra XR, a tablet for the treatment of partial onset seizures for epilepsy, as well as product filed with the FDA comprise Pristiq, a tablet for depression. The company has a license and commercialization agreement with Par Pharmaceutical, Inc. for the development and commercialization of generic Focalin XR. Its late stage development product includes Coreg CR, a capsule for heart failure and hypertension; and phase I clinical trial products include Lyrica, a capsule for Neuropathic pain and Oxycodone Hydrochloride, a controlled release capsule for pain. The company's non-generic products under development include Rexista, an oral formulation for pain relief, and Pregabalin, an extended release capsule for neuropathic pain. The company was founded in 1998 and is based in Toronto, Canada.
Is IPCI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 10.5
52 Week Low 0.46
Average Volume 383,871
200-Day Moving Average 3.9098
50-Day Moving Average 1.5071
20-Day Moving Average 0.5344
10-Day Moving Average 0.5115
Average True Range 0.1071
ADX 23.38
+DI 17.6983
-DI 29.7247
Chandelier Exit (Long, 3 ATRs ) 0.3387
Chandelier Exit (Short, 3 ATRs ) 0.7813
Upper Bollinger Band 0.6178
Lower Bollinger Band 0.451
Percent B (%b) 0.17
BandWidth 31.212575
MACD Line -0.2417
MACD Signal Line -0.3099
MACD Histogram 0.0682
Fundamentals Value
Market Cap 14.92 Million
Num Shares 31.1 Million
EPS -0.34
Price-to-Earnings (P/E) Ratio -1.41
Price-to-Sales 5.78
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.51
Resistance 3 (R3) 0.51 0.49 0.51
Resistance 2 (R2) 0.49 0.49 0.50 0.50
Resistance 1 (R1) 0.49 0.48 0.49 0.49 0.50
Pivot Point 0.47 0.47 0.48 0.48 0.47
Support 1 (S1) 0.47 0.47 0.47 0.47 0.46
Support 2 (S2) 0.45 0.46 0.46 0.46
Support 3 (S3) 0.45 0.45 0.46
Support 4 (S4) 0.45